What is Rescula?
Rescula is a synthetic docosanoid. It is a clear, colorless, viscous liquid that is practically insoluble in water.
How Does It Work?
Rescula is believed to reduce elevated intraocular pressure by increasing the outflow of fluid through the trabecular meshwork. This medication may have a local effect on BK channels and CIC-2 chloride channels, but the exact mechanism is not known.
Reasons for Using
Rescula is indicated in the treatment of open-angle glaucoma and/or ocular hypertension by lowering the intraocular pressure.
Rescula is contraindicated in anyone who is hypersensitive to unoprostone or any of its other ingredients.
Adverse Reactions for
Ocular Adverse Reactions
In 10 – 25% of Patients
- Burning, stinging, dry eyes, itching, increased length of lashes, and injection
- Increased length of lashes of greater than 1mm at 12 months in 10 -14 % of patients
- Decreased length of lashes in 7 % of patients
In 5 – 10% of Patients
Abnormal vision, eyelid disorder, foreign body sensation, and lacrimation disorder
In 1 – 5% of Patients
Blepharitis, cataract, conjunctivitis, corneal lesion, discharge form the eye, eye hemorrhage, eye pain, keratitis, irritation, photophobia, and vitreous disorder
In Less Than 1% of Patients
Acute elevated intraocular pressure, color blindness, corneal deposits, corneal edema, corneal opacity, diploplia, hyperpigmentation of the eyelid, increased number of eyelashes, iris hyperpigmentation, iritis, optic atrophy, ptosis, retinal hemorrhage, and visual field defect.
Non-Ocular Adverse Reactions
In 6 % of Patients
In 1 – 5% of Patients
Accidental injury, allergic reaction, back pain, bronchitis, increased cough, diabetes mellitus, dizziness, headache, hypertension, insomnia, pharyngitis, pain, rhinitis, and sinusitis
Side Effects and Precautions
Rescula may gradually increase the pigmentation of the iris. The pigmentation is believed to be due to increased melanin content in the melanocytes rather than an increase in the number of melanocytes. Patients who use this medication should know that there is a possibility of the increased iris pigmentation.
Rescula has been shown to cause pigment (darkening) of the periorbital tissues. It may decrease after discontinued use of the treatment.
Rescula should be used with caution in patients with active inflammation or uveitis as the medication may exacerbate the inflammation.
Macular edema and cystoid macular edema have been reported with using Rescula. It should be used with caution in patients who are at risk of developing macular edema.
Use with Contact Lenses
Contacts should be removed before instilling Rescula and not reinserted for 15 minutes.
Use in Pregnant and Nursing Women
Rescula should be used with caution as there are well controlled studies in these groups. The potential benefit should outweigh the risks for the medication.
Administration and Strength
Rescula 0.15% is instilled in the affected eye twice daily.
How is Rescula Supplied?
Rescula is supplied in a sterile ophthalmic dispensing 7.5mL bottle with 5mL.